A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human Interleukin IL-15 (rhIL-15) in Adults With Metastatic Cancers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2018
At a glance
- Drugs Interleukin-15 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 26 Jun 2018 Planned End Date changed from 1 Apr 2020 to 1 Apr 2022.
- 26 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Mar 2018 Planned number of patients changed from 44 to 52.